PHSC Valuation

Is PHSC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PHSC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PHSC (£0.24) is trading below our estimate of fair value (£0.65)

Significantly Below Fair Value: PHSC is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PHSC?

Key metric: As PHSC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PHSC. This is calculated by dividing PHSC's market cap by their current earnings.
What is PHSC's PE Ratio?
PE Ratio	21.1x
Earnings	UK£114.77k
Market Cap	UK£2.42m

PHSC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.6x
Enterprise Value/EBITDA	6.7x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does PHSC's PE Ratio compare to its peers?

The above table shows the PE ratio for PHSC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	14.8x
KOO Kooth	13.9x	11.0%	UK£59.5m
IDHC Integrated Diagnostics Holdings	13.4x	23.7%	US$220.9m
DXSP DXS International	13.1x	n/a	UK£992.3k
249A Human AdjustLtd	18.9x	n/a	JP¥510.0m
PHSC PHSC	21.1x	n/a	UK£2.4m

Price-To-Earnings vs Peers: PHSC is expensive based on its Price-To-Earnings Ratio (21.1x) compared to the peer average (14.8x).

Price to Earnings Ratio vs Industry

How does PHSC's PE Ratio compare vs other companies in the European Healthcare Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: PHSC is expensive based on its Price-To-Earnings Ratio (21.1x) compared to the European Healthcare industry average (18.2x).

Price to Earnings Ratio vs Fair Ratio

What is PHSC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PHSC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	21.1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PHSC's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

LNA Santé

€242.3m

Engages in the management and operation of health establishments.

0OR2

€23.70

-6.7%

17.3%

Arjo

SEK 8.9b

Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.

0HQ8

SEK 32.88

-6.4%

-11.8%

Guerbet

€331.6m

Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.

0ELV

€26.50

-8.0%

42.5%